Rongchang Biological: Taetisipu's application for the treatment of dry syndrome has been accepted by the CDE.

On September 9th, Rongchang Biotechnology announced on its official account that the company's independently developed innovative drug Taitsip, the world's first BLyS/APRIL dual-target fusion protein for the treatment of Sjogren's syndrome, has officially been accepted for review by the National Medical Products Administration Drug Evaluation Center, becoming the world's first biologic drug to apply for market approval in the field of Sjogren's syndrome.